These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 10888637)

  • 1. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses.
    Luzuriaga K; McManus M; Catalina M; Mayack S; Sharkey M; Stevenson M; Sullivan JL
    J Virol; 2000 Aug; 74(15):6984-91. PubMed ID: 10888637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants.
    Van der Linden D; Hainaut M; Goetghebuer T; Haelterman E; Schmitz V; Maes P; Peltier A; Levy J
    Pediatr Infect Dis J; 2007 Apr; 26(4):359-61. PubMed ID: 17414406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease.
    Al-Harthi L; Siegel J; Spritzler J; Pottage J; Agnoli M; Landay A
    AIDS; 2000 May; 14(7):761-70. PubMed ID: 10839583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral therapy in human immunodeficiency virus-infected individuals.
    Spooner KM
    Adv Intern Med; 1998; 43():373-402. PubMed ID: 9506188
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency.
    Rinaldo CR; Huang XL; Fan Z; Margolick JB; Borowski L; Hoji A; Kalinyak C; McMahon DK; Riddler SA; Hildebrand WH; Day RB; Mellors JW
    J Virol; 2000 May; 74(9):4127-38. PubMed ID: 10756025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.
    Agwu A; Lindsey JC; Ferguson K; Zhang H; Spector S; Rudy BJ; Ray SC; Douglas SD; Flynn PM; Persaud D;
    AIDS Patient Care STDS; 2008 Jul; 22(7):545-52. PubMed ID: 18479228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy.
    Kalams SA; Goulder PJ; Shea AK; Jones NG; Trocha AK; Ogg GS; Walker BD
    J Virol; 1999 Aug; 73(8):6721-8. PubMed ID: 10400770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term HIV-1 suppression in the Brazilian public health system.
    de Sa-Filho DJ; de Arruda Souza T; Golegã AA; Diaz RS; Caseiro MM
    AIDS Patient Care STDS; 2009 May; 23(5):313-4. PubMed ID: 19327023
    [No Abstract]   [Full Text] [Related]  

  • 9. A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.
    Persaud D; Pierson T; Ruff C; Finzi D; Chadwick KR; Margolick JB; Ruff A; Hutton N; Ray S; Siliciano RF
    J Clin Invest; 2000 Apr; 105(7):995-1003. PubMed ID: 10749578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous neutralizing antibody to human immunodeficiency virus-1 and replication-competent virus recovered from CD4+ T-cell reservoirs in pediatric HIV-1-infected patients on HAART.
    Ching N; Nielsen-Saines KA; Deville JG; Wei LS; Garratty E; Bryson YJ
    AIDS Res Hum Retroviruses; 2010 May; 26(5):585-91. PubMed ID: 20455762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children.
    Spiegel HM; DeFalcon E; Ogg GS; Larsson M; Beadle TJ; Tao P; McMichael AJ; Bhardwaj N; O'Callaghan C; Cox WI; Krasinski K; Pollack H; Borkowsky W; Nixon DF
    J Infect Dis; 1999 Aug; 180(2):359-68. PubMed ID: 10395850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follow-up of antiretroviral treatment in liver transplant recipients with primary and chronic HIV type 1 infection.
    Nowak P; Schvarcz R; Ericzon BG; Flamholc L; Sönnerborg A
    AIDS Res Hum Retroviruses; 2003 Jan; 19(1):13-9. PubMed ID: 12581512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection.
    Giorgi JV; Majchrowicz MA; Johnson TD; Hultin P; Matud J; Detels R
    AIDS; 1998 Oct; 12(14):1833-44. PubMed ID: 9792384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANTES production by T cells and CD8-mediated inhibition of human immunodeficiency virus gene expression before initiation of potent antiretroviral therapy predict sustained suppression of viral replication.
    Fransen S; Copeland KF; Smieja M; Smaill F; Rosenthal KL
    J Infect Dis; 2000 Feb; 181(2):505-12. PubMed ID: 10669333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy.
    Sharkey ME; Teo I; Greenough T; Sharova N; Luzuriaga K; Sullivan JL; Bucy RP; Kostrikis LG; Haase A; Veryard C; Davaro RE; Cheeseman SH; Daly JS; Bova C; Ellison RT; Mady B; Lai KK; Moyle G; Nelson M; Gazzard B; Shaunak S; Stevenson M
    Nat Med; 2000 Jan; 6(1):76-81. PubMed ID: 10613828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients.
    Daniel V; Süsal C; Melk A; Weimer R; Kröpelin M; Zimmermann R; Huth-Kühne A; Uhle C; Opelz G
    Immunol Lett; 1999 Aug; 69(2):283-9. PubMed ID: 10482364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary HIV infection in infants: impact of highly active antiretroviral therapy on the natural course.
    De Rossi A
    J Biol Regul Homeost Agents; 2002; 16(1):53-7. PubMed ID: 12003175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
    García F; Plana M; Vidal C; Cruceta A; O'Brien WA; Pantaleo G; Pumarola T; Gallart T; Miró JM; Gatell JM
    AIDS; 1999 Jul; 13(11):F79-86. PubMed ID: 10449278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mother to child transmission of HIV-1 in a Thai population: role of virus characteristics and maternal humoral immune response.
    Kittinunvorakoon C; Morris MK; Neeyapun K; Jetsawang B; Buehring GC; Hanson CV
    J Med Virol; 2009 May; 81(5):768-78. PubMed ID: 19319941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
    Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
    JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.